In vitro and in vivo studies have shown that miR-378 regulates endothelial cell function and amplifies VEGF activity to promote angiogenesis by repressing the tumor suppressors Sufu (suppressor of fused) and Fus-1 (nuclear fusion protein 1), as shown in a glioblastoma cell line [70], in non-small cell lung cancer (NSCLC) patients with brain metastases [71], and in bladder cancer [72]. Here, VEGFA is linked to neoplasm.